Study
| Phase II, single-arm, multicohort (RAGNAR) |
| Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4 alterations and disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them |
| Erdafitinib (n=217) |
Efficacy
| oRR: 30% [64 of 217 pts] |
| 12mos PFS: 15.4 % vs 0% |
| mPFS: 4.0 vs. 2.5 mos, HR:0.48, p=0.007 |
Safety
| Grade3 Aes: Stomatitis (12%), hyperphosphatemia (5%), palmar–plantar erythrodysaesthesia syndrome (6%) |
JAMA Oncol. 2023;24(8):925-935, AUG 2023
http://doi.org/10.1016/S1470-2045(23)00275-9
Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023
